The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes

Inclusion Criteria: * Age ≥ 18 years old; * No gender restrictions; * Definition of pre diabetes: All subjects were tested with 75g OGTT to measure fasting and 2h venous serum glucose and glycosylated hemoglobin. Fasting blood glucose ≥ 6.1 and \< 7mmol/L, 2-hour serum glucose ≥ 7.8 and \< 11.1mmol/L after glucose load, and glycated hemoglobin\<6.5%; * Abnormal lipid metabolism: LDL-c ≥ 3.4 mmol/L and\<4.9 mmol/L, and TG ≤ 5.6 mmol/L; (2) Non-HDL-c ≥ 4.1mmol/L and\<5.7 mmol/L, and TG ≤ 5.6 mmol/L; * Voluntarily sign the informed consent form. Exclusion Criteria: * Patients who have met the diagnosis of diabetes; * Within 3 months prior to signing the informed consent form, there was an acute coronary syndrome, stroke, or transient ischemic attack. * ALT/AST\>3 times ULN; * Known myopathy, rhabdomyolysis, or creatine kinase levels greater than 4-fold ULN, and not caused by muscle injury; * Pregnant or planning to conceive; * Have used any lipid-lowering drugs within 3 months; * Individuals with allergies/contraindications to Xuezhikang and Atorvastatin. * Suffering from any of the following diseases: uncontrolled hyperthyroidism and hypothyroidism, severe heart failure, malignant tumors, hematopoietic system diseases, digestive system diseases affecting digestion and/or absorption function, mental disorders, other serious or unstable physical diseases. * History of alcohol or drug abuse or dependence within 3 months prior to joining the trial. * Participated in clinical trials of other drugs or devices within 3 months prior to joining the trial. * Researchers believe that other situations are not suitable for participating in the experiment.